DiscGenics is a privately funded biotechnology company focused on developing advanced spinal therapeutics to treat patients with intervertebral disc diseases. It is currently developing IDCT, an off-the-shelf injectable therapeutic.
The issuance of the patent abroad extends the protection of the company’s domestic intellectual property into major international markets.
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
